Loading...

Clinical Trials

Home / Clinical Trials

Clinical Trials

Apellis is currently conducting clinical trials around the world for an array of autoimmune and inflammatory diseases, with its lead investigational drug APL-2, a complement C3 inhibitor. We believe that our approach has the potential to effectively control many complement-dependent diseases.

Learn more about Apellis-sponsored ongoing clinical trials below.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study

PEGASUS Clinical Trial: A Phase 3 study to evaluate the efficacy and safety of APL-2 (pegcetacoplan) in patients with paroxysmal nocturnal hemoglobinuria

Status

Recruiting

Learn More

pnhstudy.com

Study

PRINCE Clinical Trial: A Phase 3, randomized, multicenter, open-label, controlled study to evaluate the efficacy and safety of APL-2 (pegcetacoplan) in patients with PNH

Status

Recruiting

Learn More

clinicaltrials.gov

Study

PADDOCK Clinical Trial: Pilot study to assess safety, preliminary efficacy and pharmacokinetics of subcutaneous APL-2 (pegcetacoplan) in PNH subjects

Status

Active, not recruiting

Learn More

clinicaltrials.gov

Study

PALOMINO Clinical Trial: A Phase 2a, open-label study to evaluate the efficacy and safety of APL-2 (pegcetacoplan) in patients with PNH who have never been treated with eculizumab

Status

Active, not recruiting

Learn More

clinicaltrials.gov.

Study

PHAROAH Clinical Trial: A Phase 1 study to assess the safety of APL-2 (pegcetacoplan) as an add-on to standard of care in subjects with PNH

Status

Active, not recruiting

Learn More

clinicaltrials.gov

Study

An open-label, nonrandomized, multicenter extension study to evaluate the long term safety and efficacy of APL-2 (pegcetacoplan) in patients with PNH

Status

Enrolling by invitation

Learn More

clinicaltrials.gov

Geographic Atrophy (GA)

Study

DERBY & OAKS Clinical Trials: Two Phase 3 clinical studies of APL-2 (pegcetacoplan) therapy in patients with GA

Status

Recruiting

Learn More

gastudy.com

Autoimmune Hemolytic Anemia (AIHA)

Study

PLAUDIT Clinical Trial: A Phase 2, prospective, open-label study to assess the safety, tolerability, preliminary efficacy, pharmacokinetics and pharmacodynamics of multiple doses of APL-2 (pegcetacoplan) in patients with autoimmune hemolytic anemia (AIHA).

Status

Active, not recruiting

Nephropathies

Study

DISCOVERY Clinical Trial: Phase 2 study assessing safety and efficacy of APL-2 (pegcetacoplan) in glomerulopathies

Status

Recruiting


Apellis logo
© Apellis Pharmaceuticals 2019.